Literature DB >> 12788508

Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice.

Hans-Joachim Lüth1, Jenny Apelt, Amadi O Ihunwo, Thomas Arendt, Reinhard Schliebs.   

Abstract

Cholinergic dysfunction is a consistent feature of Alzheimer's disease, and the interrelationship between beta-amyloid deposits, inflammation and early cholinergic cell loss is still not fully understood. To characterize the mechanisms by which beta-amyloid and pro-inflammatory cytokines may exert specific degenerating actions on cholinergic cells ultrastructural investigations by electron microscopy were performed in brain sections from transgenic Tg2576 mice that express the Swedish double mutation of the human amyloid precursor protein and progressively develop beta-amyloid plaques during aging. Both light and electron microscopical investigations of the cerebral cortex of 19-month-old transgenic mice revealed a number of pathological tissue responses in close proximity of beta-amyloid plaques, such as activated microglia, astroglial proliferation, increased number of fibrous astrocytes, brain edema, degeneration of nerve cells, dendrites and axon terminals. Ultrastructural detection of choline acetyl transferase (ChAT)-immunostaining in cerebral cortical sections of transgenic mice clearly demonstrated degeneration of ChAT-immunoreactive fibres in the environment of beta-amyloid plaques and activated glial cells suggesting a role of beta-amyloid and/or inflammation in specific degeneration of cholinergic synaptic structures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788508     DOI: 10.1016/s0006-8993(03)02658-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP.

Authors:  M Dumont; R Lalonde; J-F Ghersi-Egea; K Fukuchi; C Strazielle
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

Review 2.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

3.  Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons.

Authors:  Bin Zhang; Sigrid C Veasey; Marcelo A Wood; Lewis Z Leng; Christine Kaminski; Susan Leight; Ted Abel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 4.  Gene-environment interplay in neurogenesis and neurodegeneration.

Authors:  Tomás Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

5.  Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice.

Authors:  Sylvia E Perez; Bin He; Nadeem Muhammad; Kwang-Jin Oh; Margaret Fahnestock; Milos D Ikonomovic; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2010-10-16       Impact factor: 5.996

6.  Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.

Authors:  R T Robertson; J Baratta; J Yu; F M LaFerla
Journal:  Neuroscience       Date:  2009-09-20       Impact factor: 3.590

7.  The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy.

Authors:  F Peña; Ai Gutiérrez-Lerma; R Quiroz-Baez; C Arias
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

8.  Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse.

Authors:  Sylvia E Perez; Saleem Dar; Milos D Ikonomovic; Steven T DeKosky; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2007-06-27       Impact factor: 5.996

Review 9.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

10.  Increased matrix metalloproteinase 9 activity in mild cognitive impairment.

Authors:  Martin A Bruno; Elliott J Mufson; Joanne Wuu; A Claudio Cuello
Journal:  J Neuropathol Exp Neurol       Date:  2009-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.